Age-Associated failure to adjust type i IFN receptor signaling thresholds after T cell activation

Journal of Immunology

Volumn 195, Issue 3, 2015, Pages 865-874

  Li, Guangjin ^a,b   Ju, Jihang ^a,b   Weyand, Cornelia M ^a,b   Goronzy, Jörg J ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; CD69 ANTIGEN; STAT1 PROTEIN; STAT5 PROTEIN; ALPHA BETA INTERFERON RECEPTOR; IL2 PROTEIN, HUMAN; INTERFERON; INTERLEUKIN 2; LECTIN; LEUKOCYTE ANTIGEN; PROTEIN TYROSINE PHOSPHATASE SHP 1; PTPN6 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; T LYMPHOCYTE ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; NEGATIVE FEEDBACK; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VERY ELDERLY; YOUNG ADULT; AGING; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; HUMANS; INTERFERON TYPE I; INTERLEUKIN-2; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MALE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTOR, INTERFERON ALPHA-BETA; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84937680792     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402389     Document Type: Article

References (76)

1. Weng, N. P. 2006. Aging of the immune system: how much can the adaptive immune system adapt? Immunity 24: 495-499.
2. Hakim, F. T., and R. E. Gress. 2007. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens 70: 179-189.
3. Montecino-Rodriguez, E., B. Berent-Maoz, and K. Dorshkind. 2013. Causes, consequences, and reversal of immune system aging. J. Clin. Invest. 123: 958-965.
4. Nikolich- Zugich, J. 2014. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J. Immunol. 193: 2622-2629.
5. Goronzy, J. J., F. Fang, M. M. Cavanagh, Q. Qi, and C. M. Weyand. 2015. Naive T cell maintenance and function in human aging. J. Immunol. 194: 4073-4080.
6. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
7. Nagata, N., N. Iwata, H. Hasegawa, S. Fukushi, A. Harashima, Y. Sato, M. Saijo, F. Taguchi, S. Morikawa, and T. Sata. 2008. Mouse-passaged severe acute respiratory syndrome-Associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am. J. Pathol. 172: 1625-1637.
8. Brien, J. D., J. L. Uhrlaub, A. Hirsch, C. A. Wiley, and J. Nikolich-Zugich. 2009. Key role of T cell defects in age-related vulnerability to West Nile virus. J. Exp. Med. 206: 2735-2745.
9. Zhao, J., J. Zhao, K. Legge, and S. Perlman. 2011. Age-related increases in PGD (2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J. Clin. Invest. 121: 4921-4930.
10. Petersen, L. R., A. C. Brault, and R. S. Nasci. 2013. West Nile virus: review of the literature. JAMA 310: 308-315.
11. Peiris, J. S., C. M. Chu, V. C. Cheng, K. S. Chan, I. F. Hung, L. L. Poon, K. I. Law, B. S. Tang, T. Y. Hon, C. S. Chan, et al; HKU/UCH SARS Study Group. 2003. Clinical progression and viral load in a community outbreak of coronavirus-Associated SARS pneumonia: a prospective study. Lancet 361: 1767-1772.
12. Jean, C. M., S. Honarmand, J. K. Louie, and C. A. Glaser. 2007. Risk factors for West Nile virus neuroinvasive disease, California, 2005. Emerg. Infect. Dis. 13: 1918-1920.
13. Nichol, K. L., J. D. Nordin, D. B. Nelson, J. P. Mullooly, and E. Hak. 2007. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 357: 1373-1381.
14. Targonski, P. V., R. M. Jacobson, and G. A. Poland. 2007. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 25: 3066-3069.
15. Boraschi, D., M. T. Aguado, C. Dutel, J. Goronzy, J. Louis, B. Grubeck-Loebenstein, R. Rappuoli, and G. Del Giudice. 2013. The gracefully aging immune system. Sci. Transl. Med. 5: 185ps188.
16. Duraisingham, S. S., N. Rouphael, M. M. Cavanagh, H. I. Nakaya, J. J. Goronzy, and B. Pulendran. 2013. Systems biology of vaccination in the elderly. Curr. Top. Microbiol. Immunol. 363: 117-142.
17. Dormitzer, P. R., G. Galli, F. Castellino, H. Golding, S. Khurana, G. Del Giudice, and R. Rappuoli. 2011. Influenza vaccine immunology. Immunol. Rev. 239: 167-177.
18. Goronzy, J. J., and C. M. Weyand. 2013. Understanding immunosenescence to improve responses to vaccines. Nat. Immunol. 14: 428-436.
19. Qi, Q., D. W. Zhang, C. M. Weyand, and J. J. Goronzy. 2014. Mechanisms shaping the naïve T cell repertoire in the elderly - thymic involution or peripheral homeostatic proliferation? Exp. Gerontol. 54: 71-74.
20. Nikolich-Zugich, J., M. K. Slifka, and I. Messaoudi. 2004. The many important facets of T-cell repertoire diversity. Nat. Rev. Immunol. 4: 123-132.
21. Naylor, K., G. Li, A. N. Vallejo, W. W. Lee, K. Koetz, E. Bryl, J. Witkowski, J. Fulbright, C. M. Weyand, and J. J. Goronzy. 2005. The influence of age on T cell generation and TCR diversity. J. Immunol. 174: 7446-7452.
22. Yager, E. J., M. Ahmed, K. Lanzer, T. D. Randall, D. L. Woodland, and M. A. Blackman. 2008. Age-Associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 205: 711-723.
23. Cicin-Sain, L., S. Smyk-Pearson, N. Currier, L. Byrd, C. Koudelka, T. Robinson, G. Swarbrick, S. Tackitt, A. Legasse, M. Fischer, et al. 2010. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J. Immunol. 184: 6739-6745.
24. den Braber, I., T. Mugwagwa, N. Vrisekoop, L. Westera, R. Mögling, A. B. de Boer, N. Willems, E. H. Schrijver, G. Spierenburg, K. Gaiser, et al. 2012. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 36: 288-297.
25. Qi, Q., Y. Liu, Y. Cheng, J. Glanville, D. Zhang, J.-Y. Lee, R.A. Olshen, C. M. Weyand, and J.J. Goronzy 2014. Diversity and clonal selection in the human T cell repertoire. Proc. Natl. Acad. Sci. U S A 111: 13139-13144.
26. Johnson, P. L., A. J. Yates, J. J. Goronzy, and R. Antia. 2012. Peripheral selection rather than thymic involution explains sudden contraction in naive CD4 T-cell diversity with age. Proc. Natl. Acad. Sci. USA 109: 21432-21437.
27. Haynes, L., and J. S. Lefebvre. 2011. Age-related deficiencies in antigen-specific CD4 T cell responses: lessons from mouse models. Aging Dis. 2: 374-381.
28. Haynes, L., and S. L. Swain. 2012. Aged-related shifts in T cell homeostasis lead to intrinsic T cell defects. Semin. Immunol. 24: 350-355.
29. Zhang, W., V. Brahmakshatriya, and S. L. Swain. 2014. CD4 T cell defects in the aged: causes, consequences and strategies to circumvent. Exp. Gerontol. 54: 67-70.
30. Liu, Y., and N. E. Sharpless. 2009. Tumor suppressor mechanisms in immune aging. Curr. Opin. Immunol. 21: 431-439.
31. Lee, W. W., D. Cui, M. Czesnikiewicz-Guzik, R. Z. Vencio, I. Shmulevich, A. Aderem, C. M. Weyand, and J. J. Goronzy. 2008. Age-dependent signature of metallothionein expression in primary CD4 T cell responses is due to sustained zinc signaling. Rejuvenation Res. 11: 1001-1011.
32. Gomez, I., F. Marx, E. A. Gould, and B. Grubeck-Loebenstein. 2004. T cells from elderly persons respond to neoantigenic stimulation with an unimpaired IL-2 production and an enhanced differentiation into effector cells. Exp. Gerontol. 39: 597-605.
33. Li, G., M. Yu, W. W. Lee, M. Tsang, E. Krishnan, C. M. Weyand, and J. J. Goronzy. 2012. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat. Med. 18: 1518-1524.
34. Yu, M., G. Li, W. W. Lee, M. Yuan, D. Cui, C. M. Weyand, and J. J. Goronzy. 2012. Signal inhibition by the dual-specific phosphatase 4 impairs T celldependent B-cell responses with age. Proc. Natl. Acad. Sci. USA 109: E879-E888.
35. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4: 44-57.
36. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37: 1-13.
37. Takaoka, A., and H. Yanai. 2006. Interferon signalling network in innate defence. Cell. Microbiol. 8: 907-922.
38. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189: 521-530.
39. Lombardi, G., P. J. Dunne, D. Scheel-Toellner, T. Sanyal, D. Pilling, L. S. Taams, P. Life, J. M. Lord, M. Salmon, and A. N. Akbar. 2000. Type 1 IFN maintains the survival of anergic CD4+ T cells. J. Immunol. 165: 3782-3789.
40. Shiow, L. R., D. B. Rosen, N. Brdicková, Y. Xu, J. An, L. L. Lanier, J. G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon-Alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540-544.
41. Oviedo-Orta, E., C. K. Li, and R. Rappuoli. 2013. Perspectives on vaccine development for the elderly. Curr. Opin. Immunol. 25: 529-534.
42. Khurana, S., W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, M. T. Rock, K. M. Edwards, G. Del Giudice, R. Rappuoli, and H. Golding. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2: ra5.
43. Galli, G., D. Medini, E. Borgogni, L. Zedda, M. Bardelli, C. Malzone, S. Nuti, S. Tavarini, C. Sammicheli, A. K. Hilbert, et al. 2009. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 106: 3877-3882.
44. Couch, R. B., P. Winokur, R. Brady, R. Belshe, W. H. Chen, T. R. Cate, B. Sigurdardottir, A. Hoeper, I. L. Graham, R. Edelman, et al. 2007. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25: 7656-7663.
45. Oxman, M. N., M. J. Levin, G. R. Johnson, K. E. Schmader, S. E. Straus, L. D. Gelb, R. D. Arbeit, M. S. Simberkoff, A. A. Gershon, L. E. Davis, et al; Shingles Prevention Study Group. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352: 2271-2284.
46. Belardelli, F., and I. Gresser. 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17: 369-372.
47. Santini, S. M., C. Lapenta, M. Logozzi, S. Parlato, M. Spada, T. Di Pucchio, and F. Belardelli. 2000. Type I interferon as a powerful adjuvant for monocytederived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191: 1777-1788.
48. Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D. F. Tough. 2001. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
49. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D. F. Tough. 2003. Cross-priming of CD8+ T cells stimulated by virusinduced type I interferon. Nat. Immunol. 4: 1009-1015.
50. Bracci, L., V. La Sorsa, F. Belardelli, and E. Proietti. 2008. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev. Vaccines 7: 373-381.
51. Kolumam, G. A., S. Thomas, L. J. Thompson, J. Sprent, and K. Murali-Krishna. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202: 637-650.
52. Le Bon, A., C. Thompson, E. Kamphuis, V. Durand, C. Rossmann, U. Kalinke, and D. F. Tough. 2006. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176: 2074-2078.
53. Dondi, E., L. Rogge, G. Lutfalla, G. Uzé, and S. Pellegrini. 2003. Downmodulation of responses to type I IFN upon T cell activation. J. Immunol. 170: 749-756.
54. Zella, D., F. Romerio, S. Curreli, P. Secchiero, C. Cicala, D. Zagury, and R. C. Gallo. 2000. IFN-Alpha 2b reduces IL-2 production and IL-2 receptor function in primary CD4+ T cells. J. Immunol. 164: 2296-2302.
55. Matikainen, S., T. Sareneva, T. Ronni, A. Lehtonen, P. J. Koskinen, and I. Julkunen. 1999. Interferon-Alpha activates multiple STAT proteins and upregulates proliferation-Associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 93: 1980-1991.
56. Trinchieri, G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207: 2053-2063.
57. Rauch, I., M. Müller, and T. Decker. 2013. The regulation of inflammation by interferons and their STATs. JAK-STAT 2: e23820.
58. Ivashkiv, L. B., and L. T. Donlin. 2014. Regulation of type I interferon responses. Nat. Rev. Immunol. 14: 36-49.
59. Nguyen, K. B., W. T. Watford, R. Salomon, S. R. Hofmann, G. C. Pien, A. Morinobu, M. Gadina, J. J. O'Shea, and C. A. Biron. 2002. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297: 2063-2066.
60. Tanabe, Y., T. Nishibori, L. Su, R. M. Arduini, D. P. Baker, and M. David. 2005. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-Alpha beta responses in T lymphocytes. J. Immunol. 174: 609-613.
61. Kallal, L. E., and C. A. Biron. 2013. Changing partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections. JAK-STAT 2: e23504.
62. David, M., H. E. Chen, S. Goelz, A. C. Larner, and B. G. Neel. 1995. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15: 7050-7058.
63. You, M., D. H. Yu, and G. S. Feng. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19: 2416-2424.
64. Du, Z., Y. Shen, W. Yang, I. Mecklenbrauker, B. G. Neel, and L. B. Ivashkiv. 2005. Inhibition of IFN-Alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proc. Natl. Acad. Sci. USA 102: 10267-10272.
65. Wormald, S., and D. J. Hilton. 2004. Inhibitors of cytokine signal transduction. J. Biol. Chem. 279: 821-824.
66. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7: 454-465.
67. Zimmerer, J. M., G. B. Lesinski, S. V. Kondadasula, V. I. Karpa, A. Lehman, A. Raychaudhury, B. Becknell, and W. E. Carson, III. 2007. IFN-Alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J. Immunol. 178: 4832-4845.
68. Dimitriou, I. D., L. Clemenza, A. J. Scotter, G. Chen, F. M. Guerra, and R. Rottapel. 2008. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol. Rev. 224: 265-283.
69. Piganis, R. A., N. A. De Weerd, J. A. Gould, C. W. Schindler, A. Mansell, S. E. Nicholson, and P. J. Hertzog. 2011. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-Associated tyrosine kinase Tyk2. J. Biol. Chem. 286: 33811-33818.
70. Ungureanu, D., S. Vanhatupa, N. Kotaja, J. Yang, S. Aittomaki, O. A. Jänne, J. J. Palvimo, and O. Silvennoinen. 2003. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 102: 3311-3313.
71. Liu, B., S. Mink, K. A. Wong, N. Stein, C. Getman, P. W. Dempsey, H. Wu, and K. Shuai. 2004. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 5: 891-898.
72. Tough, D. F. 2012. Modulation of T-cell function by type I interferon. Immunol. Cell Biol. 90: 492-497.
73. Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, and H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosisinducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189: 1451-1460.
74. Oshima, K., N. Yanase, C. Ibukiyama, A. Yamashina, N. Kayagaki, H. Yagita, and J. Mizuguchi. 2001. Involvement of TRAIL/TRAIL-R interaction in IFNalpha-induced apoptosis of Daudi B lymphoma cells. Cytokine 14: 193-201.
75. Takada, E., K. Shimo, K. Hata, M. Abiake, Y. Mukai, M. Moriyama, L. Heasley, and J. Mizuguchi. 2005. Interferon-beta-induced activation of c-Jun NH2-terminal kinase mediates apoptosis through up-regulation of CD95 in CH31 B lymphoma cells. Exp. Cell Res. 304: 518-530.
76. Fraietta, J. A., Y. M. Mueller, G. Yang, A. C. Boesteanu, D. T. Gracias, D. H. Do, J. L. Hope, N. Kathuria, S. E. McGettigan, M. G. Lewis, et al. 2013. Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog. 9: e1003658.